Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

155.83 +0.58 (+0.37%)
Streaming Delayed Price Updated: 10:54 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand and GSK Expand Global Collaboration and License Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Meme Stock Breakdown
There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. 
Via Talk Markets
Ligand Pharmaceuticals Sees RS Rating Rise To 92
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb... 
Via Benzinga
Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript
LGND earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Recap: Ligand Pharmaceuticals Q3 Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Ligand Reports Third Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Ligand to Report Third Quarter Financial Results on November 9, 2021
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants... 
Via Benzinga
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Stock Shows Rising Price Performance
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. 
Via Investor's Business Daily
Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating
Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82. 
Via Investor's Business Daily
Why Digital Turbine's Stock Is Trading Higher Today
Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ... 
Via Benzinga
Topics Stocks
Digital Turbine Added To S&P MidCap 400 Index
Media and mobile communications company Digital Turbine Inc (NASDAQ: 
Via Benzinga
Topics Stocks
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
From Ligand Pharmaceuticals
Via Business Wire
What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months
Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy... 
Via Benzinga
Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript
LGND earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Ligand Reports Second Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
Ligand to Report Second Quarter Financial Results on July 29, 2021
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS